We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Observational Study of the Preventive Trial With HIV-1 Tat Protein (ISS OBS P-001)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01024764
First Posted: December 3, 2009
Last Update Posted: March 1, 2011
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Istituto Superiore di Sanità
December 2, 2009
December 3, 2009
March 1, 2011
November 2007
Not Provided
To evaluate the persistence of specific immune responses, volunteers will be monitored for anti-Tat specific antibodies, anti-Tat proliferative response and in vitro γIFN and IL-4 production in response to Tat (Elispot).
Same as current
Complete list of historical versions of study NCT01024764 on ClinicalTrials.gov Archive Site
To develop test procedures in order to evaluate humoral and cellular anti-Tat immunity for future efficacy trials.
Same as current
Not Provided
Not Provided
 
Observational Study of the Preventive Trial With HIV-1 Tat Protein
Observational Study of the Phase I Safety and Immunogenicity Trial of Recombinant HIV-1 Tat in HIV-1 Uninfected Adult Volunteers

The results of the Phase I Safety and Immunogenicity Trial of Recombinant HIV-1 Tat (ISS P-001 and ISS T-001) indicate that the vaccine based on the recombinant Tat protein is safe, well tolerated and immunogenic. The present study is intended to extend the follow-up of the volunteers for additional 3 years to evaluate the persistence of the anti-Tat humoral and cellular immune response. The results of the present study will be key for the design of future phase II trials, particularly for the definition of the optimal schedule for boosting immunizations.

All individuals (20) will be enrolled in a 120-weeks observational study and monitored every 24 weeks for the following 3 years. During these visits, in addition to the hematological and biochemical assessment, the anti-Tat specific humoral and cellular immune responses will be evaluated.

Not Provided
Observational
Time Perspective: Prospective
Not Provided
Retention:   Samples Without DNA
Description:
Whole blood, serum, PBMCs
Non-Probability Sample
Healthy Subjects previously included in the Preventive Phase I Clinical Trial with Tat protein
Healthy Subjects
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
5
December 2010
Not Provided

Inclusion Criteria:

  • Previous participation to the Phase I Clinical Trial ISS P-001
Sexes Eligible for Study: All
18 Years to 50 Years   (Adult)
Yes
Contact information is only displayed when the study is recruiting subjects
Italy
 
 
NCT01024764
ISS OBS P-001
No
Not Provided
Not Provided
Barbara Ensoli, CNAIDS - Istituto Superiore di Sanita
Istituto Superiore di Sanità
Not Provided
Principal Investigator: Pasquale Narciso, MD I.R.C.C.S. Spallanzani Hospital, Rome
Principal Investigator: Aldo Di Carlo, MD S. Gallicano Hospital- Rome
Principal Investigator: Adriano Lazzarin, MD San Raffaele Hospital - Milan
Istituto Superiore di Sanità
February 2010